Lupin Atlantis Holdings SA, Switzerland, (LAHSA), wholly owned subsidiary of Lupin Limited, has signed an Asset Purchase Agreement with Sanofi, a French multinational pharmaceutical and healthcare company, for acquiring a portfolio of accretive established products in Europe and Canada.

Sanofi is a French multinational pharmaceutical and healthcare company. The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired. The turnover of the said brands in these markets for the year ended March 31, 2023 was about US$ 6.49.

The brands being acquired are in line with the business of the Company.

The proposed transaction is of strategic interest by bringing accretive assets in the respiratory field to help structure the company's new respiratory franchise in Germany following the launch of Luforbec in Germany, the launch of Gx Spiriva and the acquisition of Xopenex and Brovana in the US.

The purchase consideration for the above acquisition is € 10 million plus sales milestones up to € 8 million, contingent upon future sales.